Vance Coffman - Amgen Insider

AMGN -- USA Stock  

USD 185.01  1.06  0.58%

Lead Independent Director

Dr. Vance D. Coffman is the Lead Independent Director of Amgen Inc. Dr. Coffman was a director of 3M Company, a consumer and office products and services company, since 2002 and he was a director of Deere Company, a farm and construction machinery company, since 2004. He serves on the Compensation Committee and chairs the Finance Committee of 3M Company and serves on the Corporationrationrate Governance and Executive Committees and chairs the Compensation Committee of Deere Company. Dr. Coffman was also director of BristolMyers Squibb Company, a pharmaceutical company, and a member of its Audit and Governance Committees, from 1998 to 2007. Dr. Coffman was the Chairman of the Board and Chief Executive Officer of Lockheed Martin Corporationrationration, an aerospace and defense company, from 1998 to 2005, and was ex officio member of all board committees. From 1997 to 1998, he was Vice Chairman of the Board and Chief Executive Officer of Lockheed Martin. He is currently on the Board of Trustees of the Naval Postgraduate School Foundation, the Stanford Engineering Advisory Council of Stanford University and the Board of Governors of the Iowa State University Foundation. Dr. Coffman was a Member of the National Academy of Engineering since 1997 and a Fellow of the American Institute of Aeronautics and Astronautics and the American Astronautical Society since 1989 and 1997, respectively
Age: 71  Director Since 2013  Ph.D    
Coffman received an undergraduate degree from Iowa State University and a doctorate from Stanford University.

Vance Coffman Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.84 % which means that it generated profit of $8.84 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 9.59 % meaning that it created $9.59 on every $100 dollars invested by stockholders.
The company currently holds 35.54 B in liabilities with Debt to Equity (D/E) ratio of 227.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Fred WeissAllergan plc
Ralph AlvarezEli Lilly and Company
Peter WendellMerck Co
William MontagueEndo International plc
Phebe NovakovicAbbott Laboratories
William SpenglerEndo International plc
Leslie BrunMerck Co
Lewis CampbellBristol Myers Squibb Company
JoAnn ReedMallinckrodt Public Limited Com
Roxanne AustinAbbott Laboratories
Elaine UllianVertex Pharmaceuticals Incorpor
James BloemAllergan plc
Jeffrey EdwardsBio Rad Laboratories
Erik FyrwaldEli Lilly and Company
Dinesh PaliwalBristol Myers Squibb Company
Alice SchwartzBio Rad Laboratories
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
Shane CookeEndo International plc
Nancy HutsonEndo International plc
Daniel StarksAbbott Laboratories
Craig ThompsonMerck Co

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ. It employs 20800 people.Amgen (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Amgen Leadership Team

Frank Herringer, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Wanda Austin, Director
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance Indicators

Current Sentiment - AMGN

Amgen Investor Sentiment
Majority of Macroaxis users are presently bullish on Amgen. What is your sentiment towards investing in Amgen? Are you bullish or bearish?
98% Bullish
2% Bearish

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Amgen and IQVIA Holdings. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Aroon Oscillator module to analyze current equity momentum using aroon oscillator and other momentum ratios.